Arcus Biosciences reported a net loss of $106 million for Q4 2025 on revenues of $33 million. The company is pivoting its focus toward its HIF-2a inhibitor, casdatifan, following the wind-down of certain TIGIT programs, and maintains a strong cash position of over $1 billion.

Arcus Biosciences reported a total revenue of $28 million for the first quarter of 2025, a significant decrease from $145 million in the same period of 2024. The company recorded a net loss of $112 million, compared to a net loss of $4 million in Q1 2024. Despite the financial results, Arcus maintained a strong cash position with $1.0 billion in cash, cash equivalents, and marketable securities.

Arcus Biosciences reported a net loss of $94 million for Q4 2024, an increase from $81 million in Q4 2023, despite an increase in total revenues to $36 million. The company ended the year with a strong cash position of $992 million, positioning it well for upcoming pivotal readouts.

Arcus Biosciences reported Q3 2024 financial results with revenues of $48 million and a net loss of $92 million. The company's cash, cash equivalents, and marketable securities totaled $1.1 billion, expected to fund operations into mid-2027. Key pipeline updates were provided, including progress in casdatifan and domvanalimab development.

Arcus Biosciences reported second-quarter revenue of $39 million and a net loss of $93 million. The company's cash, cash equivalents, and marketable securities totaled $1.0 billion, expected to fund operations into 2027. Enrollment completed for Phase 3 study STAR-221, and multiple data presentations for Casdatifan are expected.

Arcus Biosciences reported Q1 2024 financial results, including revenues of $145 million and a net loss of $4 million. The company highlighted its strong cash position of $1.1 billion, expected to fund operations into 2027, and advancements in its pipeline with upcoming data presentations at ASCO and expected completion of enrollment for Phase 3 studies.

Arcus Biosciences reported revenues of $31 million and a net loss of $81 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $866 million at the end of the year, which, combined with a recent equity investment, is expected to fund operations into 2027.

Arcus Biosciences reported $32 million in revenues for Q3 2023, with a net loss of $71 million. The company's cash reserves are expected to fund operations into 2026, supporting ongoing clinical trials and research programs.

Arcus Biosciences reported revenues of $29 million for the second quarter of 2023, compared to $27 million for the same period in 2022. Cash, cash equivalents and marketable securities were $1.0 billion as of June 30, 2023. Net loss was $75 million for the quarter.

Arcus Biosciences reported $25 million in revenues and a net loss of $80 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities were $1.0 billion as of March 31, 2023, expected to fund operations into 2026. Clinical development activities are expanding, with multiple Phase 3 and Phase 2 trials ongoing.

Arcus Biosciences reported fourth-quarter and full-year 2022 financial results. The company's cash, cash equivalents, and marketable securities were $1.1 billion. Revenues were $34 million for the fourth quarter 2022, and net loss was $67 million.

Arcus Biosciences reported Q3 2022 financial results, highlighting a strategic amendment to the ARC-10 Phase 3 study and advancements in its clinical pipeline, including the initiation of the ARC-20 Phase 1/1b study. The company's cash, cash equivalents, and marketable securities totaled $1.2 billion, sufficient to fund operations into 2026.

Arcus Biosciences reported collaboration and license revenues of $26.8 million for the second quarter ended June 30, 2022, and a net loss of $66.6 million. The company's cash, cash equivalents, and investments totaled $1.27 billion, expected to fund operations into 2026. They are advancing clinical programs, including four registrational Phase 3 trials with domvanalimab-based combinations.

Arcus Biosciences reported positive results from its ARC-7 study and has a strong cash position of $1.3 billion to fund operations into 2026. The company is advancing its pipeline with multiple Phase 3 trials planned.

Arcus Biosciences reported strong financial results for Q4 2021, driven by license revenue from Gilead's option exercise. The company is advancing its clinical programs with a strong cash position, including multiple Phase 3 studies for domvanalimab.

Arcus Biosciences reported its Q3 2021 financial results, highlighting the initiation of Gilead's opt-in review process for their anti-TIGIT program and providing updates on their clinical studies, including ARC-7 and ARC-8. The company ended the quarter with $743.4 million in cash and investments, expecting it to fund operations through at least 2023.

Arcus Biosciences reported its second quarter 2021 financial results, highlighting the advancement of its clinical-stage molecules and partnerships, particularly with Gilead. The company ended the quarter with $805.1 million in cash and investments, and collaboration revenue was $9.5 million. Net loss for the quarter was $76.0 million.

Arcus Biosciences reported its Q1 2021 financial results, highlighting a cash balance of $884.9 million and collaboration revenues of $9.5 million. The company is advancing its clinical trials, including the anti-TIGIT program and studies for AB680 and etrumadenant.

Arcus Biosciences reported fourth-quarter financial results, highlighting a cash balance of $735.1 million and an additional $220.4 million received from Gilead after year-end. The company is advancing its pipeline, including registrational trials for domvanalimab and multiple data readouts expected in 2021.

Arcus Biosciences announced financial results for the third quarter ended September 30, 2020. The company reported a net income of $1.8 million, a significant increase compared to the net loss of $22.4 million for the same period in the prior year. The increase was primarily attributable to revenue recognized under the Gilead agreements.

Arcus Biosciences reported a net loss of $45.1 million for the second quarter of 2020. The company strengthened its balance sheet by raising approximately $348 million in gross proceeds from a public offering and established a 10-year global partnership with Gilead.

Arcus Biosciences reported a net loss of $27.8 million for the first quarter ended March 31, 2020. Collaboration and license revenue was $1.8 million. Research and development expenses were $23.1 million, and general and administrative expenses were $7.0 million. Cash, cash equivalents and investments in marketable securities were $157.9 million as of March 31, 2020.

Arcus Biosciences reported a net loss of $16.6 million for the fourth quarter of 2019, with collaboration and license revenue of $9.8 million. The company's cash, cash equivalents, and investments totaled $188.3 million as of December 31, 2019.